

NaveniBright™ PD1/PD-L1 BOND RX

ILLUMINATING FUNCTION IN SPATIAL PROTEOMICS


Automated detection of PD1/PD-L1 interactions *in situ*

Immune checkpoint therapy (ICT) responses can vary among patients, underscoring the need for improved predictive biomarkers to refine patient stratification. Although PD-L1 immunohistochemistry (IHC) is widely used, the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear¹. Preliminary data show that the PD1/PD-L1 interaction may be a predictive biomarker for ICT response in NSCLC, providing more information than the current clinical standard of PD-L1 IHC². Now, Navinci introduces the NaveniBright™ PD1/PD-L1 BOND RX in collaboration with Leica Biosystems for enhanced reproducibility and throughput.

NaveniBright™ PD1/PD-L1 BOND RX enables you to:


- Visualize the precise interaction of PD1/PD-L1 within the tissue microenvironment.
- Evaluate the potential of PD1/PD-L1 interaction as a biomarker with a high throughput automated kit.
- Achieve heightened efficiency and reproducibility through an automated workflow, streamlining your research process.
- Save valuable time with the automated workflow, minimizing hands-on time and maximizing productivity.





How it works

The NaveniBright™ PD1/PD-L1 BOND RX kit uses the Naveni® *in situ* proximity ligation technology. It includes primary antibodies and Navenibodies (orange in the illustration). When in close proximity, they trigger a rolling circle amplification reaction, creating a strong, distinct dot. Optimized for the BOND RX Fully Automated Research Stainer, the kit has been rigorously verified across diverse FFPE tissues and three research sites, ensuring robust performance.



PD1/PD-L1 interaction in head and neck
cancer, Squamous cell carcinoma.

PD1/PD-L1 interaction in germinal centers, lymph node.

Catalog nr	Kit	Target	Description
60031	NaveniBright BOND RX	Your choice, use primary antibodies with host origin of mouse and rabbit	Anti-mouse Navenibody Anti-rabbit Navenibody Buffers for blocking and dilutions and detection reagents Reagents sufficient for 30 FFPE tissue slides, including dead volumes*
60032	NaveniBright PD1/PD-L1 BOND RX	Human PD1/PD-L1 interaction	Navenibody targeting human PD1 protein based on clone EH33 CST Navenibody targeting human PD-L1 protein based on clone SP142 Abcam RabMAb® Buffers for blocking and dilutions and detection reagents for the PD1/PD-L1 interaction signal Reagents sufficient for 30 FFPE tissue slides, including dead volumes*

*additional reagents required, read more on navinci.se/technology/naveni-bond
Research use only, not for use in diagnostic procedures

1) Sánchez-Magraner L, et al., High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Res 80, 19 (2020)
2) Micic P, et al., PD1-PDL1 interaction as a superior predictor for response to immune checkpoint therapy in NSCLC patients. AACR 2024 7-10 April; San Diego (CA); Abstract nr 5139



YOU HAVE THE VISION,
WE HAVE THE SUBSTANCE.

Your Distributor:

BIOMOL GmbH

Kieler Straße 303a · 22525 Hamburg · Germany

info@biomol.de · www.biomol.de · www.biomol.com

Fon: 040-853 260 0 · Fax: 040-853 260 22

TOLL FREE IN GERMANY:

Fon: 0800-246 66 51 · Fax: 0800-246 66 52

For research use only.
Not for use in diagnostic or therapeutic procedures.

